* ANNOUNCES APPROVAL OF ZEPZELCA (LURBINECTEDIN) FOR TREATMENT OF METASTATIC SMALL CELL LUNG CANCER IN SWITZERLAND
PharmaMar (MSE: PHM) has announced today the initiation of a new Phase I clinical trial with PM534, a novel marine-derived anti-tumor compound resulting from the Company's research program for the treatment of solid tumors.
The ONCOLIBERYX project, led by PharmaMar (MSE:PHM), brings together four leading Spanish research groups in nanotechnology and oncology, to develop unique formulations that could lead to new oncology therapies based on the marine compounds in PharmaMar's collection.
MADRID, Jan 11 (Reuters) - Spain's PharmaMar (PHMR.MC) said on Tuesday trials made in vitro and on animals showed its Plitidepsin drug had positive antiviral effects on the variants of COVID-19, including Omicron.
Madrid, Dec. 22, 2021 /PRNewswire/ -- PharmaMar (MSE: PHM) has announced today a new license and commercialization agreement with the Eczac?ba?? Pharmaceuticals Marketing Co. to commercialize the anticancer drug lurbinectedin in Turkey.
MADRID and DUBLIN, Dec. 13, 2021 /PRNewswire/ -- PharmaMar (MSE: PHM) and partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the initiation of a confirmatory Phase 3 clinical trial, LAGOON, evaluating Zepzelca® (lurbinectedin) for the treatment of patients with relapsed small cell lung cancer (SCLC). The trial will measure overall survival (OS) as the primary endpoint and progression-free survival (PFS) as a secondary endpoint of lurbinectedin monotherapy or lurbinectedin in combination with irinotecan compared with investigator's choice of topotecan or irinotecan, in patients with SCLC whose disease has progressed following prior platinum-containing chemotherapy with or without anti-PD-1 or anti-PD-L1 agents.
Madrid, November 11th , 2021. – PharmaMar S.A. (MSE:PHM) has announced today a licensing agreement with Lotus Pharmaceutical CO., LTD. (TWSE:1795) to commercialize the anticancer drug lurbinectedin in Taiwan.
(Reuters) -Spanish pharmaceutical group PharmaMar on Thursday said its nine-month net profit slipped 58% to 54.7 million euros ($63.92 million) from a year ago when it booked a hefty gain from a licence payment.
Madrid, September 30th n, 2021. – PharmaMar (MSE:PHM) has announced today nthat its licensing partner, Jazz Pharmaceuticals plc (Nasdaq: JAZZ), has received nconditional approval from Health Canada for ZepzelcaTM (lurbinectedin) for the ntreatment of adult patients with relapsed stage III or metastatic small cell lung cancer n(SCLC), with disease progression on or after platinum-based chemotherapy. nLurbinectedin will be available in Canada later this year
SINGAPORE, Sept. 22, 2021 /PRNewswire/ -- SINGAPORE patients with an aggressive form of lung cancer (metastatic small cell lung cancer) can now access a new therapy that may improve outcomes.